#South Korea #Seoul #Sacituzumab #NSCLC #Pembrolizumab

Trial Results Summary

In the ongoing search for effective treatments for metastatic non-small cell lung cancer (NSCLC), the EVOKE-03/KEYNOTE-D46 trial was presented at the International Association for the Study of Lung Cancer (IASLC) conference, shedding light on combination therapies involving Sacituzumab govitecan (SG) and pembrolizumab. The phase 3 study aimed to evaluate whether this combination could offer better progression-free survival (PFS) and overall survival (OS) compared to pembrolizumab alone for patients with high levels of PD-L1 expression.

Findings

In this extensive study involving 620 participants, researchers reported that while the combination therapy produced numerically longer progression-free survival, it failed to achieve statistical significance against pembrolizumab monotherapy. Specifically, patients receiving SG plus pembrolizumab experienced a median PFS of 11.8 months, compared to 7.7 months for those treated with pembrolizumab alone, resulting in a hazard ratio (HR) of 0.81 (95% CI, 0.66-1.00; P=0.0252).

Despite the favorable numerical results, further analysis indicated no significant improvement in overall survival rates between the two groups. For SG plus pembrolizumab, the median OS was recorded at 21.5 months, showing a slight decrease when juxtaposed with the 22.8 months for pembrolizumab solo treatment (HR, 1.07; 95% CI, 0.85-1.35; P=0.7155).

Dr. Giannis Mountzios, a leading researcher from the Henry Dunant Hospital Center in Athens, Greece, commented on these findings by stating, “While the combination therapy shows potential due to its numerically longer progression-free survival and higher response rates, it did not meet the necessary threshold for statistical significance.”

Study Methodology

The EVOKE-03/KEYNOTE-D46 study was structured as an open-label phase 3 trial, engaging patients who had not received previous treatment for metastatic NSCLC and whose tumors displayed a PD-L1 tumor proportion score (TPS) of at least 50%. Participants were randomized to either receive SG at a dose of 10 mg/kg intravenously on specific days alongside Pembrolizumab or pembrolizumab alone.

The dual primary endpoints focused on progression-free survival measured via blinded independent central review and overall survival outcomes.

Results Summary

An overview of the response rates indicates a notable objective response rate of 55.6% for the SG and pembrolizumab combination, in contrast to 43.7% for the pembrolizumab-only group. Furthermore, the disease control rate between the two groups distinctly highlighted 83.3% for the combination versus 73.1% for pembrolizumab alone, with a nearly identical duration of response at about 21.4 months for the combination and 21.3 months for monotherapy.

Safety Profile

Delving into the safety aspect, treatment-related adverse events were reported among 93.2% of the combination group versus 65.4% of those who received pembrolizumab alone. Severe grade 3 or higher adverse events were prevalent in 55.7% of the combination arm, indicating a significantly heightened risk compared to 16.5% in the monotherapy group. Common adverse events noted included anemia, alopecia, neutropenia, diarrhea, and nausea. Dr. Mountzios affirmed that the safety profile remained consistent with existing knowledge concerning both drugs, revealing no new or unexpected toxicities.

Conclusion

Given the trial outcomes, it is clear that although the combination of Sacituzumab govitecan and pembrolizumab holds promise for heightened response rates, it ultimately did not prove sufficient for statistical significance in overall treatment effectiveness for untreated PD-L1-high metastatic NSCLC patients. The ongoing research and development of treatment strategies remains vital as healthcare professionals seek to optimize care for this patient population.

About the IASLC

The International Association for the Study of Lung Cancer is dedicated to the global fight against lung cancer, fostering collaboration among specialists worldwide.

For more detailed insights into this study and its implications, visit IASLC.org for extensive resources on lung cancer research and treatment.